

SOFDRA - (12.45% ; Gel)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | SOFPIRONIUM | Innovator | BOTANIX SB INC. |
| Dosage | 12.45% ; Gel | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | SOFDRA is an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.